Vaccine

Page semi-protected
Source: Wikipedia, the free encyclopedia.
(Redirected from
Vaccine platform
)
For other uses, see Vaccine (disambiguation).

Vaccine
Smallpox vaccine and equipment for administering it
MeSHD014612
Part of a series on
Vaccination
General information
Vaccines
Issues

A vaccine is a biological

infectious or malignant disease.[1][2] The safety and effectiveness of vaccines has been widely studied and verified.[3][4]
A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and recognize further and destroy any of the microorganisms associated with that agent that it may encounter in the future.

Vaccines can be

sterilizing immunity, in which infection is prevented completely.[9]

The administration of vaccines is called

preventable infections.[11]

The first recorded use of inoculation to prevent smallpox occurred in the 16th century in China, with the earliest hints of the practice in China coming during the 10th century.[12] It was also the first disease for which a vaccine was produced.[13][14] The folk practice of inoculation against smallpox was brought from Turkey to Britain in 1721 by Lady Mary Wortley Montagu.[15] The terms vaccine and vaccination are derived from Variolae vaccinae (smallpox of the cow), the term devised by Edward Jenner (who both developed the concept of vaccines and created the first vaccine) to denote cowpox. He used the phrase in 1798 for the long title of his Inquiry into the Variolae vaccinae Known as the Cow Pox, in which he described the protective effect of cowpox against smallpox.[16] In 1881, to honor Jenner, Louis Pasteur proposed that the terms should be extended to cover the new protective inoculations then being developed.[17] The science of vaccine development and production is termed vaccinology.

Infectious diseases before and after a vaccine was introduced. Vaccinations have a direct effect on the diminishment of the number of cases and contributes indirectly to a diminishment of the number of deaths.

Effects

A child with measles, a vaccine-preventable disease[18]

There is overwhelming scientific consensus that vaccines are a very safe and effective way to fight and eradicate infectious diseases.[19][20][21][22] The immune system recognizes vaccine agents as foreign, destroys them, and "remembers" them. When the virulent version of an agent is encountered, the body recognizes the protein coat on the agent, and thus is prepared to respond, by first neutralizing the target agent before it can enter cells, and secondly by recognizing and destroying infected cells before that agent can multiply to vast numbers.[23][24]

Limitations to their effectiveness, nevertheless, exist.[25] Sometimes, protection fails for vaccine-related reasons such as failures in vaccine attenuation, vaccination regimens or administration.[26]

Failure may also occur for host-related reasons if the host's immune system does not respond adequately or at all. Host-related lack of response occurs in an estimated 2-10% of individuals, due to factors including genetics, immune status, age, health and nutritional status.[26] One type of primary immunodeficiency disorder resulting in genetic failure is X-linked agammaglobulinemia, in which the absence of an enzyme essential for B cell development prevents the host's immune system from generating antibodies to a pathogen.[27][28]

Host–pathogen interactions and responses to infection are dynamic processes involving multiple pathways in the immune system.

adaptive immunity can take 1–2 weeks to fully develop. During that time, the host can still become infected.[31]

Once antibodies are produced, they may promote immunity in any of several ways, depending on the class of antibodies involved. Their success in clearing or inactivating a pathogen will depend on the amount of antibodies produced and on the extent to which those antibodies are effective at countering the strain of the pathogen involved, since different strains may be differently susceptible to a given immune reaction.[30] In some cases vaccines may result in partial immune protection (in which immunity is less than 100% effective but still reduces risk of infection) or in temporary immune protection (in which immunity wanes over time) rather than full or permanent immunity. They can still raise the reinfection threshold for the population as a whole and make a substantial impact.

morbidity, faster recovery from illness, and a wide range of other effects.[33][34]

Those who are older often display less of a response than those who are younger, a pattern known as Immunosenescence.[35] Adjuvants commonly are used to boost immune response, particularly for older people whose immune response to a simple vaccine may have weakened.[36]

The efficacy or performance of the vaccine is dependent on several factors:

  • the disease itself (for some diseases vaccination performs better than for others)
  • the strain of vaccine (some vaccines are specific to, or at least most effective against, particular strains of the disease)[37]
  • whether the vaccination schedule has been properly observed.
  • idiosyncratic response to vaccination; some individuals are "non-responders" to certain vaccines, meaning that they do not generate antibodies even after being vaccinated correctly.
  • assorted factors such as ethnicity, age, or genetic predisposition.

If a vaccinated individual does develop the disease vaccinated against (breakthrough infection), the disease is likely to be less virulent than in unvaccinated cases.[38]

Important considerations in an effective vaccination program:[39]

  1. careful modeling to anticipate the effect that an immunization campaign will have on the epidemiology of the disease in the medium to long term
  2. ongoing surveillance for the relevant disease following introduction of a new vaccine
  3. maintenance of high immunization rates, even when a disease has become rare

In 1958, there were 763,094 cases of measles in the United States; 552 deaths resulted.[40][41] After the introduction of new vaccines, the number of cases dropped to fewer than 150 per year (median of 56).[41] In early 2008, there were 64 suspected cases of measles. Fifty-four of those infections were associated with importation from another country, although only thirteen percent were actually acquired outside the United States; 63 of the 64 individuals either had never been vaccinated against measles or were uncertain whether they had been vaccinated.[41]

Vaccines led to the eradication of

eradication campaign that has seen endemic polio restricted to only parts of three countries (Afghanistan, Nigeria, and Pakistan).[43] However, the difficulty of reaching all children, cultural misunderstandings, and disinformation have caused the anticipated eradication date to be missed several times.[44][45][46][47]

Vaccines also help prevent the development of antibiotic resistance. For example, by greatly reducing the incidence of pneumonia caused by Streptococcus pneumoniae, vaccine programs have greatly reduced the prevalence of infections resistant to penicillin or other first-line antibiotics.[48]

The measles vaccine is estimated to prevent a million deaths every year.[49]

Adverse effects

Main article:
Adverse vaccine event

Vaccinations given to children, adolescents, or adults are generally safe.[50][51] Adverse effects, if any, are generally mild.[52] The rate of side effects depends on the vaccine in question.[52] Some common side effects include fever, pain around the injection site, and muscle aches.[52] Additionally, some individuals may be allergic to ingredients in the vaccine.[53] MMR vaccine is rarely associated with febrile seizures.[51]

Host-("vaccinee")-related determinants that render a person susceptible to infection, such as

virus transmission.[26]

Severe side effects are extremely rare.

immunodeficient individuals, and rotavirus vaccines are moderately associated with intussusception.[51]

At least 19 countries have no-fault compensation programs to provide compensation for those with severe adverse effects of vaccination.[54] The United States' program is known as the National Childhood Vaccine Injury Act, and the United Kingdom employs the Vaccine Damage Payment.

Types

Illustration with the text "There are three main approaches to making a vaccine: Using a whole virus or bacterium Parts that trigger the immune system Just the genetic material."

Vaccines typically contain attenuated, inactivated or dead organisms or purified products derived from them. There are several types of vaccines in use.[55] These represent different strategies used to try to reduce the risk of illness while retaining the ability to induce a beneficial immune response.

Attenuated

Main article: Attenuated vaccine

Some vaccines contain live,

BCG" used to elicit an immune response to the vaccine. The live attenuated vaccine containing strain Yersinia pestis EV is used for plague immunization. Attenuated vaccines have some advantages and disadvantages. Attenuated, or live, weakened, vaccines typically provoke more durable immunological responses. But they may not be safe for use in immunocompromised individuals, and on rare occasions mutate to a virulent form and cause disease.[56]

Inactivated

Main article: Inactivated vaccine

Some vaccines contain inactivated, but previously virulent, micro-organisms that have been destroyed with chemicals, heat, or radiation

influenza vaccines.[59]

Avian flu vaccine development by reverse genetics
techniques

Toxoid

Main article: Toxoid

Crotalus atrox toxoid is used to vaccinate dogs against rattlesnake bites.[60]

Subunit

Main article: Subunit vaccine

Rather than introducing an inactivated or attenuated micro-organism to an immune system (which would constitute a "whole-agent" vaccine), a

human papillomavirus (HPV), which is composed of the viral major capsid protein.[62] Another example is the hemagglutinin and neuraminidase subunits of the influenza virus.[59] A subunit vaccine is being used for plague immunization.[63]

Conjugate

Main article: Conjugate vaccine

Certain bacteria have a polysaccharide

immunogenic. By linking these outer coats to proteins (e.g., toxins), the immune system can be led to recognize the polysaccharide as if it were a protein antigen. This approach is used in the Haemophilus influenzae type B vaccine.[64]

Outer membrane vesicle

Outer membrane vesicles (OMVs) are naturally immunogenic and can be manipulated to produce potent vaccines. The best known OMV vaccines are those developed for serotype B meningococcal disease.[65][66]

Heterotypic

Main article: Heterologous vaccine

Heterologous vaccines also known as "Jennerian vaccines", are vaccines that are pathogens of other animals that either do not cause disease or cause mild disease in the organism being treated. The classic example is Jenner's use of cowpox to protect against smallpox. A current example is the use of BCG vaccine made from Mycobacterium bovis to protect against tuberculosis.[67]

Genetic vaccine

Main article: Genetic vaccine

Genetic vaccines are based on the principle of uptake of a nucleic acid into cells, whereupon a protein is produced according to the nucleic acid template. This protein is usually the immunodominant antigen of the pathogen or a surface protein that enables the formation of neutralizing antibodies. The subgroup of genetic vaccines encompass viral vector vaccines, RNA vaccines and DNA vaccines.[citation needed]

Viral vector

Main article: Viral vector vaccine

Viral vector vaccines use a safe virus to insert pathogen genes in the body to produce specific antigens, such as surface proteins, to stimulate an immune response.[68][69]

RNA

Main article:
RNA vaccine

An mRNA vaccine (or

emergency use authorization in some countries. For example, the Pfizer-BioNTech vaccine and Moderna mRNA vaccine are approved for use in adults and children in the US.[71][72][73]

DNA

Main article: DNA vaccine

A DNA vaccine uses a DNA plasmid (pDNA)) that encodes for an antigenic protein originating from the pathogen upon which the vaccine will be targeted. pDNA is inexpensive, stable, and relatively safe, making it an excellent option for vaccine delivery.[74]

This approach offers a number of potential advantages over traditional approaches, including the stimulation of both B- and T-cell responses, improved vaccine stability, the absence of any infectious agent and the relative ease of large-scale manufacture.[75]

Experimental

Many innovative vaccines are also in development and use.

While most vaccines are created using inactivated or attenuated compounds from micro-organisms, synthetic vaccines are composed mainly or wholly of synthetic peptides, carbohydrates, or antigens.

Valence

Vaccines may be monovalent (also called univalent) or multivalent (also called polyvalent). A monovalent vaccine is designed to immunize against a single antigen or single microorganism.[81] A multivalent or polyvalent vaccine is designed to immunize against two or more strains of the same microorganism, or against two or more microorganisms.[82] The valency of a multivalent vaccine may be denoted with a Greek or Latin prefix (e.g., bivalent, trivalent, or tetravalent/quadrivalent). In certain cases, a monovalent vaccine may be preferable for rapidly developing a strong immune response.[83]

Interactions

When two or more vaccines are mixed in the same formulation, the two vaccines can interfere. This most frequently occurs with live attenuated vaccines, where one of the vaccine components is more robust than the others and suppresses the growth and immune response to the other components.[84]

This phenomenon was first[

dengue vaccines, where the DEN-3 serotype was found to predominate and suppress the response to DEN-1, -2 and -4 serotypes.[86]

Other contents

This section is an excerpt from Vaccine ingredients.[edit]
Graphic from the World Health Organization describing the main ingredients typically in vaccines
A vaccine dose contains many ingredients (stabilizers, adjuvants, residual inactivating ingredients, residual cell culture materials, residual antibiotics and preservatives) very little of which is the active ingredient, the immunogen. A single dose may have merely nanograms of virus particles, or micrograms of bacterial polysaccharides. A vaccine injection, oral drops or nasal spray is mostly water. Other ingredients are added to boost the immune response, to ensure safety or help with storage, and a tiny amount of material is left-over from the manufacturing process. Very rarely, these materials can cause an allergic reaction in people who are very sensitive to them.

Adjuvants

Main article: Immunologic adjuvant

Vaccines typically contain one or more adjuvants, used to boost the immune response. Tetanus toxoid, for instance, is usually adsorbed onto alum. This presents the antigen in such a way as to produce a greater action than the simple aqueous tetanus toxoid. People who have an adverse reaction to adsorbed tetanus toxoid may be given the simple vaccine when the time comes for a booster.[87]

In the preparation for the 1990 Persian Gulf campaign, the whole cell

pertussis vaccine was used as an adjuvant for anthrax vaccine. This produces a more rapid immune response than giving only the anthrax vaccine, which is of some benefit if exposure might be imminent.[88]

Preservatives

Vaccines may also contain preservatives to prevent contamination with

fungi. Until recent years, the preservative thiomersal (a.k.a. Thimerosal in the US and Japan) was used in many vaccines that did not contain live viruses. As of 2005, the only childhood vaccine in the U.S. that contains thiomersal in greater than trace amounts is the influenza vaccine,[89] which is currently recommended only for children with certain risk factors.[90] Single-dose influenza vaccines supplied in the UK do not list thiomersal in the ingredients. Preservatives may be used at various stages of the production of vaccines, and the most sophisticated methods of measurement might detect traces of them in the finished product, as they may in the environment and population as a whole.[91]

Many vaccines need preservatives to prevent serious adverse effects such as

autism, no convincing scientific evidence supports these claims.[94] Furthermore, a 10–11-year study of 657,461 children found that the MMR vaccine does not cause autism and actually reduced the risk of autism by seven percent.[95][96]

Excipients

Beside the active vaccine itself, the following excipients and residual manufacturing compounds are present or may be present in vaccine preparations:[97]

Nomenclature

Various fairly standardized abbreviations for vaccine names have developed, although the standardization is by no means centralized or global. For example, the vaccine names used in the United States have well-established abbreviations that are also widely known and used elsewhere. An extensive list of them provided in a sortable table and freely accessible is available at a US Centers for Disease Control and Prevention web page.[99] The page explains that "The abbreviations [in] this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, ACIP Work Groups, the editor of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison organizations to the ACIP."[99]

Some examples are "

DTaP" for diphtheria and tetanus toxoids and acellular pertussis vaccine, "DT" for diphtheria and tetanus toxoids, and "Td" for tetanus and diphtheria toxoids. At its page on tetanus vaccination,[100] the CDC further explains that "Upper-case letters in these abbreviations denote full-strength doses of diphtheria (D) and tetanus (T) toxoids and pertussis (P) vaccine. Lower-case "d" and "p" denote reduced doses of diphtheria and pertussis used in the adolescent/adult-formulations. The 'a' in DTaP and Tdap stands for 'acellular', meaning that the pertussis component contains only a part of the pertussis organism."[100]

Another list of established vaccine abbreviations is at the CDC's page called "Vaccine Acronyms and Abbreviations", with abbreviations used on U.S. immunization records.[101] The United States Adopted Name system has some conventions for the word order of vaccine names, placing head nouns first and adjectives postpositively. This is why the USAN for "OPV" is "poliovirus vaccine live oral" rather than "oral poliovirus vaccine".

Licensing

A vaccine licensure occurs after the successful conclusion of the development cycle and further the clinical trials and other programs involved through Phases I–III demonstrating safety, immunoactivity, immunogenetic safety at a given specific dose, proven effectiveness in preventing infection for target populations, and enduring preventive effect (time endurance or need for revaccination must be estimated).[102] Because preventive vaccines are predominantly evaluated in healthy population cohorts and distributed among the general population, a high standard of safety is required.[103] As part of a multinational licensing of a vaccine, the World Health Organization Expert Committee on Biological Standardization developed guidelines of international standards for manufacturing and quality control of vaccines, a process intended as a platform for national regulatory agencies to apply for their own licensing process.[102] Vaccine manufacturers do not receive licensing until a complete clinical cycle of development and trials proves the vaccine is safe and has long-term effectiveness, following scientific review by a multinational or national regulatory organization, such as the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA).[104][105]

Upon developing countries adopting WHO guidelines for vaccine development and licensure, each country has its own responsibility to issue a national licensure, and to manage, deploy, and monitor the vaccine throughout its use in each nation.[102] Building trust and acceptance of a licensed vaccine among the public is a task of communication by governments and healthcare personnel to ensure a vaccination campaign proceeds smoothly, saves lives, and enables economic recovery.[106][107] When a vaccine is licensed, it will initially be in limited supply due to variable manufacturing, distribution, and logistical factors, requiring an allocation plan for the limited supply and which population segments should be prioritized to first receive the vaccine.[106]

World Health Organization

Vaccines developed for multinational distribution via the United Nations Children's Fund (UNICEF) require pre-qualification by the WHO to ensure international standards of quality, safety, immunogenicity, and efficacy for adoption by numerous countries.[102]

The process requires manufacturing consistency at WHO-contracted laboratories following

Good Manufacturing Practice (GMP).[102] When UN agencies are involved in vaccine licensure, individual nations collaborate by 1) issuing marketing authorization and a national license for the vaccine, its manufacturers, and distribution partners; and 2) conducting postmarketing surveillance, including records for adverse events after the vaccination program. The WHO works with national agencies to monitor inspections of manufacturing facilities and distributors for compliance with GMP and regulatory oversight.[102]

Some countries choose to buy vaccines licensed by reputable national organizations, such as EMA, FDA, or national agencies in other affluent countries, but such purchases typically are more expensive and may not have distribution resources suitable to local conditions in developing countries.[102]

European Union

In the European Union (EU), vaccines for pandemic pathogens, such as

seasonal influenza, are licensed EU-wide where all the member states comply ("centralized"), are licensed for only some member states ("decentralized"), or are licensed on an individual national level.[104] Generally, all EU states follow regulatory guidance and clinical programs defined by the European Committee for Medicinal Products for Human Use (CHMP), a scientific panel of the European Medicines Agency (EMA) responsible for vaccine licensure.[104] The CHMP is supported by several expert groups who assess and monitor the progress of a vaccine before and after licensure and distribution.[104]

United States

Under the FDA, the process of establishing evidence for vaccine clinical safety and efficacy is the same as for

Biologics License Application which must provide a scientific review team (from diverse disciplines, such as physicians, statisticians, microbiologists, chemists) and comprehensive documentation for the vaccine candidate having efficacy and safety throughout its development. Also during this stage, the proposed manufacturing facility is examined by expert reviewers for GMP compliance, and the label must have a compliant description to enable health care providers' definition of vaccine-specific use, including its possible risks, to communicate and deliver the vaccine to the public.[108] After licensure, monitoring of the vaccine and its production, including periodic inspections for GMP compliance, continue as long as the manufacturer retains its license, which may include additional submissions to the FDA of tests for potency, safety, and purity for each vaccine manufacturing step.[108]

India

Drugs Controller General of India is the head of department of the Central Drugs Standard Control Organization of the Government of India responsible for approval of licences of specified categories of drugs such as vaccines AND others like blood and blood products, IV fluids, and sera in India.[109]

Postmarketing surveillance

Until a vaccine is in use for the general population, all potential

Phase IV studies for postmarketing surveillance of the vaccine while it is used widely in the public.[102][108] The WHO works with UN member states to implement post-licensing surveillance.[102] The FDA relies on a Vaccine Adverse Event Reporting System to monitor safety concerns about a vaccine throughout its use in the American public.[108]

Scheduling

Main article: Vaccination schedule
For country-specific information on vaccination policies and practices, see Vaccination policy.

In order to provide the best protection, children are recommended to receive vaccinations as soon as their immune systems are sufficiently developed to respond to particular vaccines, with additional "booster" shots often required to achieve "full immunity". This has led to the development of complex vaccination schedules. Global recommendations of vaccination schedule are issued by

pertussis, tetanus, HiB, chickenpox, rotavirus, influenza, meningococcal disease and pneumonia.[112]

The large number of vaccines and boosters recommended (up to 24 injections by age two) has led to problems with achieving full compliance. To combat declining compliance rates, various notification systems have been instituted and many combination injections are now marketed (e.g., Pentavalent vaccine and MMRV vaccine), which protect against multiple diseases.

Besides recommendations for infant vaccinations and boosters, many specific vaccines are recommended for other ages or for repeated injections throughout life – most commonly for measles, tetanus, influenza, and pneumonia. Pregnant women are often screened for continued resistance to rubella. The

shingles, a disease caused by the chickenpox virus, which usually affects the elderly.[115]

Scheduling and dosing of a vaccination may be tailored to the level of immunocompetence of an individual[116] and to optimize population-wide deployment of a vaccine when it supply is limited,[117] e.g. in the setting of a pandemic.

Economics of development

Main article: Economics of vaccines

One challenge in vaccine development is economic: Many of the diseases most demanding a vaccine, including HIV, malaria and tuberculosis, exist principally in poor countries. Pharmaceutical firms and biotechnology companies have little incentive to develop vaccines for these diseases because there is little revenue potential. Even in more affluent countries, financial returns are usually minimal and the financial and other risks are great.[118]

Most vaccine development to date has relied on "push" funding by government, universities and non-profit organizations.[119] Many vaccines have been highly cost effective and beneficial for public health.[120] The number of vaccines actually administered has risen dramatically in recent decades.[121] This increase, particularly in the number of different vaccines administered to children before entry into schools may be due to government mandates and support, rather than economic incentive.[122]

Patents

According to the World Health Organization, the biggest barrier to vaccine production in less developed countries has not been

human papillomavirus vaccine, the patents may impose an additional barrier.[123]

When increased production of vaccines was urgently needed during the COVID-19 pandemic in 2021, the World Trade Organization and governments around the world evaluated whether to waive intellectual property rights and patents on COVID-19 vaccines, which would "eliminate all potential barriers to the timely access of affordable COVID-19 medical products, including vaccines and medicines, and scale up the manufacturing and supply of essential medical products".[124]

Production

Vaccine production is fundamentally different from other kinds of manufacturing – including regular pharmaceutical manufacturing – in that vaccines are intended to be administered to millions of people of whom the vast majority are perfectly healthy.[125] This fact drives an extraordinarily rigorous production process with strict compliance requirements that go far beyond what is required of other products.[125]

Depending upon the antigen, it can cost anywhere from US$50 to $500 million to build a vaccine production facility, which requires highly specialized equipment, clean rooms, and containment rooms.[126] There is a global scarcity of personnel with the right combination of skills, expertise, knowledge, competence and personality to staff vaccine production lines.[126] With the notable exceptions of Brazil, China, and India, many developing countries' educational systems are unable to provide enough qualified candidates, and vaccine makers based in such countries must hire expatriate personnel to keep production going.[126]

Vaccine production has several stages. First, the antigen itself is generated. Viruses are grown either on primary cells such as chicken eggs (e.g., for influenza) or on continuous cell lines such as cultured human cells (e.g., for hepatitis A).[127] Bacteria are grown in bioreactors (e.g., Haemophilus influenzae type b). Likewise, a recombinant protein derived from the viruses or bacteria can be generated in yeast, bacteria, or cell cultures.[128][129]

After the antigen is generated, it is isolated from the cells used to generate it. A virus may need to be inactivated, possibly with no further purification required. Recombinant proteins need many operations involving ultrafiltration and column chromatography. Finally, the vaccine is formulated by adding adjuvant, stabilizers, and preservatives as needed. The adjuvant enhances the immune response to the antigen, stabilizers increase the storage life, and preservatives allow the use of multidose vials.[128][129] Combination vaccines are harder to develop and produce, because of potential incompatibilities and interactions among the antigens and other ingredients involved.[130]

The final stage in vaccine manufacture before distribution is fill and finish, which is the process of filling vials with vaccines and packaging them for distribution. Although this is a conceptually simple part of the vaccine manufacture process, it is often a bottleneck in the process of distributing and administering vaccines.[131][132][133]

Vaccine production techniques are evolving. Cultured mammalian cells are expected to become increasingly important, compared to conventional options such as chicken eggs, due to greater productivity and low incidence of problems with contamination. Recombination technology that produces genetically detoxified vaccines is expected to grow in popularity for the production of bacterial vaccines that use toxoids. Combination vaccines are expected to reduce the quantities of antigens they contain, and thereby decrease undesirable interactions, by using pathogen-associated molecular patterns.[130]

Vaccine manufacturers

The companies with the highest market share in vaccine production are

Sinopharm (CNPGC) alone providing over 85% of the doses for 14 different vaccines in China.[134]: 48  Brazil is approaching the point of supplying its own domestic needs using technology transferred from the developed world.[134]
: 49 

Delivery systems

A woman receiving a vaccine by injection

One of the most common methods of delivering vaccines into the human body is injection.

The development of new delivery systems raises the hope of vaccines that are safer and more efficient to deliver and administer. Lines of research include liposomes and ISCOM (immune stimulating complex).[135]

Notable developments in vaccine delivery technologies have included oral vaccines. Early attempts to apply oral vaccines showed varying degrees of promise, beginning early in the 20th century, at a time when the very possibility of an effective oral antibacterial vaccine was controversial.[136] By the 1930s there was increasing interest in the prophylactic value of an oral typhoid fever vaccine for example.[137]

An oral polio vaccine turned out to be effective when vaccinations were administered by volunteer staff without formal training; the results also demonstrated increased ease and efficiency of administering the vaccines. Effective oral vaccines have many advantages; for example, there is no risk of blood contamination. Vaccines intended for oral administration need not be liquid, and as solids, they commonly are more stable and less prone to damage or spoilage by freezing in transport and storage.[138] Such stability reduces the need for a "cold chain": the resources required to keep vaccines within a restricted temperature range from the manufacturing stage to the point of administration, which, in turn, may decrease costs of vaccines.

A microneedle approach, which is still in stages of development, uses "pointed projections fabricated into arrays that can create vaccine delivery pathways through the skin".[139]

An experimental needle-free[140] vaccine delivery system is undergoing animal testing.[141][142] A stamp-size patch similar to an adhesive bandage contains about 20,000 microscopic projections per square cm.[143] This dermal administration potentially increases the effectiveness of vaccination, while requiring less vaccine than injection.[144]

In veterinary medicine

See also: Influenza vaccine § Veterinary use, and Vaccination of dogs
sheep pox and pleural pneumonia

Vaccinations of animals are used both to prevent their contracting diseases and to prevent transmission of disease to humans.[145] Both animals kept as pets and animals raised as livestock are routinely vaccinated. In some instances, wild populations may be vaccinated. This is sometimes accomplished with vaccine-laced food spread in a disease-prone area and has been used to attempt to control rabies in raccoons.

Where rabies occurs, rabies vaccination of dogs may be required by law. Other canine vaccines include

parainfluenza virus, and Lyme disease
, among others.

Cases of veterinary vaccines used in humans have been documented, whether intentional or accidental, with some cases of resultant illness, most notably with

orders of magnitude
more economical than the human one.

DIVA vaccines

DIVA (Differentiation of Infected from Vaccinated Animals), also known as SIVA (Segregation of Infected from Vaccinated Animals) vaccines, make it possible to differentiate between infected and vaccinated animals. DIVA vaccines carry at least one epitope less than the equivalent wild microorganism. An accompanying diagnostic test that detects the antibody against that epitope assists in identifying whether the animal has been vaccinated or not.[citation needed]

The first DIVA vaccines (formerly termed marker vaccines and since 1999 coined as DIVA vaccines) and companion diagnostic tests were developed by J. T. van Oirschot and colleagues at the Central Veterinary Institute in Lelystad, The Netherlands.[147][148] They found that some existing vaccines against pseudorabies (also termed Aujeszky's disease) had deletions in their viral genome (among which was the gE gene). Monoclonal antibodies were produced against that deletion and selected to develop an ELISA that demonstrated antibodies against gE. In addition, novel genetically engineered gE-negative vaccines were constructed.[149] Along the same lines, DIVA vaccines and companion diagnostic tests against bovine herpesvirus 1 infections have been developed.[148][150]

The DIVA strategy has been applied in various countries to successfully eradicate pseudorabies virus from those countries. Swine populations were intensively vaccinated and monitored by the companion diagnostic test and, subsequently, the infected pigs were removed from the population. Bovine herpesvirus 1 DIVA vaccines are also widely used in practice.[citation needed] Considerable efforts are ongoing to apply the DIVA principle to a wide range of infectious diseases, such as classical swine fever,[151] avian influenza,[152] Actinobacillus pleuropneumonia[153] and Salmonella infections in pigs.[154]

History

Further information: Vaccination § History, and Inoculation § Origins
Comparison of smallpox (left) and cowpox inoculations sixteen days after administration (1802)

Prior to the introduction of vaccination with material from cases of cowpox (heterotypic immunisation), smallpox could be prevented by deliberate variolation with smallpox virus. The earliest hints of the practice of variolation for smallpox in China come during the tenth century.[155][further explanation needed] The Chinese also practiced the oldest documented use of variolation, dating back to the fifteenth century. They implemented a method of "nasal insufflation" administered by blowing powdered smallpox material, usually scabs, up the nostrils. Various insufflation techniques have been recorded throughout the sixteenth and seventeenth centuries within China.[156]: 60  Two reports on the Chinese practice of inoculation were received by the Royal Society in London in 1700; one by Martin Lister who received a report by an employee of the East India Company stationed in China and another by Clopton Havers.[157] In France, Voltaire reports that the Chinese have practiced variolation "these hundred years".[158]

An early 19th-century satire of antivaxxers by Isaac Cruikshank

Mary Wortley Montagu, who had witnessed variolation in Turkey, had her four-year-old daughter variolated in the presence of physicians of the Royal Court in 1721 upon her return to England.[156] Later on that year, Charles Maitland conducted an experimental variolation of six prisoners in Newgate Prison in London.[159] The experiment was a success, and soon variolation was drawing attention from the royal family, who helped promote the procedure. However, in 1783, several days after Prince Octavius of Great Britain was inoculated, he died.[160] In 1796, the physician Edward Jenner took pus from the hand of a milkmaid with cowpox, scratched it into the arm of an 8-year-old boy, James Phipps, and six weeks later variolated the boy with smallpox, afterwards observing that he did not catch smallpox.[161][162] Jenner extended his studies and, in 1798, reported that his vaccine was safe in children and adults, and could be transferred from arm-to-arm, which reduced reliance on uncertain supplies from infected cows.[160] In 1804, the Spanish Balmis smallpox vaccination expedition to Spain's colonies Mexico and Philippines used the arm-to-arm transport method to get around the fact the vaccine survived for only 12 days in vitro. They used cowpox.[163] Since vaccination with cowpox was much safer than smallpox inoculation,[164] the latter, though still widely practiced in England, was banned in 1840.[165]

French print in 1896 marking the centenary of Jenner's vaccine

Following on from Jenner's work, the second generation of vaccines was introduced in the 1880s by

growth media and cell culture replaced eggs as the standard method of virus propagation for vaccines.[166]

Vaccinology flourished in the twentieth century, which saw the introduction of several successful vaccines, including those against

eradication of smallpox during the 1960s and 1970s. Maurice Hilleman was the most prolific of the developers of the vaccines in the twentieth century. As vaccines became more common, many people began taking them for granted. However, vaccines remain elusive for many important diseases, including herpes simplex, malaria, gonorrhea, and HIV.[161][167]

Generations of vaccines

First generation vaccines are whole-organism vaccines – either live and

AIDS). While killed vaccines do not have this risk, they cannot generate specific killer T-cell responses and may not work at all for some diseases.[168]

Second generation vaccines were developed to reduce the risks from live vaccines. These are subunit vaccines, consisting of specific protein antigens (such as tetanus or diphtheria toxoid) or recombinant protein components (such as the hepatitis B surface antigen). They can generate TH and antibody responses, but not killer T cell responses.[citation needed]

BNT162b2 were developed in the year 2020 with the help of Operation Warp Speed and massively deployed to combat the COVID-19 pandemic. In 2021, Katalin Karikó and Drew Weissman received Columbia University's Horwitz Prize for their pioneering research in mRNA vaccine technology.[173]

Trends

Since at least 2013, scientists have been trying to develop synthetic third-generation vaccines by reconstructing the outside structure of a virus; it was hoped that this will help prevent vaccine resistance.[174]

Principles that govern the immune response can now be used in tailor-made vaccines against many noninfectious human diseases, such as cancers and autoimmune disorders.

regulatory science, political, cultural, and social responses.[177]

Plants as bioreactors for vaccine production

The idea of vaccine production via

transgenic plants was identified as early as 2003. Plants such as tobacco, potato, tomato, and banana can have genes inserted that cause them to produce vaccines usable for humans.[178] In 2005, bananas were developed that produce a human vaccine against hepatitis B.[179]

Vaccine hesitancy

After the December 2020 introduction of COVID vaccines, a partisan gap in death rates developed, indicating the effects of vaccine skepticism.[180] As of March 2024, more than 30 percent of Republicans had not received a Covid vaccine, compared with less than 10 percent of Democrats.[180]

vaccine-preventable diseases.[189][190][191][192][193][194] The World Health Organization therefore characterized vaccine hesitancy as one of the top ten global health threats in 2019.[195][196]

See also

References

  1. ^ "Expanded Practice Standards" (PDF). Iowa Administrative Code. 2019. Archived (PDF) from the original on 2023-01-19. Retrieved 2023-01-16.
  2. ^ "Immunization: The Basics". Centers for Disease Control and Prevention. 22 November 2022. Archived from the original on 12 July 2023. Retrieved July 8, 2023.
  3. PMID 34129355. The effect of vaccines on public health is truly remarkable. One study examining the impact of childhood vaccination on the 2001 US birth cohort found that vaccines prevented 33,000 deaths and 14 million cases of disease (Zhou et al. 2005). Among 73 nations supported by the GAVI alliance, mathematical models project that vaccines will prevent 23.3 million deaths from 2011–2020 compared to what would have occurred if there were no vaccines available (Lee et al. 2013). Vaccines have been developed against a wide assortment of human pathogens. {{cite book}}: |journal= ignored (help
    )
  4. ^ Zimmer, Carl (20 November 2020). "2 Companies Say Their Vaccines Are 95% Effective. What Does That Mean? You might assume that 95 out of every 100 people vaccinated will be protected from Covid-19. But that's not how the math works". The New York Times. Archived from the original on 22 November 2020. Retrieved 21 November 2020.
  5. PMID 26214521
    .
  6. PMID 26861670
    .
  7. doi:10.2217/fvl.15.60
    .
  8. PMID 24748633
    .
  9. S2CID 221180503
    .
  10. ^ *United States Centers for Disease Control and Prevention (2011). A CDC framework for preventing infectious diseases. Archived 2017-08-29 at the Wayback Machine Accessed 11 September 2012. "Vaccines are our most effective and cost-saving tools for disease prevention, preventing untold suffering and saving tens of thousands of lives and billions of dollars in healthcare costs each year."
  11. ^ World Health Organization, Global Vaccine Action Plan 2011-2020. Archived 2014-04-14 at the Wayback Machine Geneva, 2012.
  12. ^ Williams 2010, p. 60.
  13. S2CID 6688481
    .
  14. PMID 6319980
    .
  15. ^ Ferguson, Donna (28 March 2021). "How Mary Wortley Montagu's bold experiment led to smallpox vaccine – 75 years before Jenner". the Guardian. Archived from the original on 11 July 2022. Retrieved 11 July 2022.
  16. PMID 9987167
    .
  17. ^
    doi:10.1016/s0140-6736(02)35739-8
    .
  18. ^ "Measles Vaccination CDC". 2018-02-05. Archived from the original on 2019-11-19. Retrieved 2018-11-13.
  19. PMID 3879673
    .
  20. ^ "The science is clear: Vaccines are safe, effective, and do not cause autism". The Hub. 2017-01-11. Archived from the original on 2017-09-28. Retrieved 2019-04-16.
  21. PMID 9018282
    .
  22. ^ "Vaccine Safety: The Facts". HealthyChildren.org. Archived from the original on 2019-04-16. Retrieved 2019-04-16.
  23. ISBN 978-0-12-385245-8. Archived
    from the original on 18 April 2022. Retrieved 18 April 2022.
  24. PMID 21572612
    .
  25. PMID 19393917
    .
  26. ^
    PMID 26836329
    .
  27. PMID 29939682
    . Retrieved 18 April 2022.
  28. S2CID 1922332
    .
  29. PMID 31827066
    .
  30. ^ a b Janeway, Charles A Jr.; Travers, Paul; Walport, Mark; Shlomchik, Mark J. (2001). "The Humoral Immune Response". Immunobiology: The Immune System in Health and Disease (5th ed.). Archived from the original on 2 January 2021. Retrieved 18 April 2022.
  31. PMID 29939682. Archived
    from the original on 12 November 2021. Retrieved 18 April 2022.
  32. PMID 15178201
    .
  33. PMID 27123182
    .
  34. ISBN 978-953-51-2530-3. Archived
    from the original on 14 January 2023. Retrieved 19 April 2022.
  35. PMID 33021823
    .
  36. ^ Neighmond P (2010-02-07). "Adapting Vaccines For Our Aging Immune Systems". Morning Edition. NPR. Archived from the original on 2013-12-16. Retrieved 2014-01-09.
  37. PMID 10435956
    .
  38. PMID 12955637
    .
  39. PMID 12176861
    .
  40. PMID 15106120
    .
  41. ^
    PMID 18463608. Archived
    from the original on October 11, 2017.
  42. ^ "WHO | Smallpox". WHO. World Health Organization. Archived from the original on 2007-09-22. Retrieved 2019-04-16.
  43. ^ "WHO South-East Asia Region certified polio-free". WHO. 27 March 2014. Archived from the original on 27 March 2014. Retrieved November 3, 2014.
  44. ^ "Statement following the Twenty-Eighth IHR Emergency Committee for Polio". World Health Organization. 21 May 2021. Archived from the original on 19 April 2022. Retrieved 19 April 2022.
  45. PMID 23798688
    .
  46. PMID 33705246
    .
  47. ^ "Disinformation disturbs anti-polio drives". The Express Tribune. 24 January 2022. Archived from the original on 10 May 2022. Retrieved 19 April 2022.
  48. ^ "19 July 2017 Vaccines promoted as key to stamping out drug-resistant microbes "Immunization can stop resistant infections before they get started, say scientists from industry and academia."". Archived from the original on July 22, 2017.
  49. ^ Sullivan P (2005-04-13). "Maurice R. Hilleman dies; created vaccines". Wash. Post. Archived from the original on 2012-10-20. Retrieved 2014-01-09.
  50. S2CID 215751248
    .
  51. ^
    PMID 25086160. Archived
    from the original on 2020-01-30. Retrieved 2019-07-01.
  52. ^ a b c "Possible Side-effects from Vaccines". Centers for Disease Control and Prevention. 2018-07-12. Archived from the original on 17 March 2017. Retrieved 24 February 2014.
  53. ^ "Seasonal Flu Shot – Seasonal Influenza". CDC. 2018-10-02. Archived from the original on 2015-10-01. Retrieved 2017-09-17.
  54. PMID 21556305. Archived from the original
    on August 11, 2013.
  55. National Institute of Allergy and Infectious Diseases. 2012-04-03. Archived
    from the original on 2015-09-05. Retrieved 2015-01-27.
  56. ISBN 978-81-89781-09-5
    . Retrieved 2014-01-09.
  57. ^ "Types of Vaccines". Archived from the original on 2017-07-29. Retrieved October 19, 2017.
  58. S2CID 219331100. Archived
    from the original on 2021-04-25. Retrieved 2021-04-25.
  59. ^ a b c d "Different Types of Vaccines | History of Vaccines". www.historyofvaccines.org. Archived from the original on 2019-01-26. Retrieved 2019-06-14.
  60. ^ "Types of Vaccines". coastalcarolinaresearch.com. Archived from the original on 2019-05-03. Retrieved 2019-05-03.
  61. ^ Philadelphia, The Children's Hospital of (2014-08-18). "A Look at Each Vaccine: Hepatitis B Vaccine". www.chop.edu. Archived from the original on 2019-05-31. Retrieved 2019-06-14.
  62. ^ "HPV Vaccine | Human Papillomavirus | CDC". www.cdc.gov. 2019-05-13. Archived from the original on 2019-06-18. Retrieved 2019-06-14.
  63. PMID 8745007
    .
  64. ^ "Polysaccharide Protein Conjugate Vaccines". www.globalhealthprimer.emory.edu. Archived from the original on 2019-06-23. Retrieved 2019-06-14.
  65. ^
    PMID 33353987
    .
  66. PMID 26912077
    .
  67. ^ Scott (April 2004). "Classifying Vaccines" (PDF). BioProcesses International: 14–23. Archived (PDF) from the original on 2013-12-12. Retrieved 2014-01-09.
  68. ^ "Vaccine Types". Vaccines.org. Office of Infectious Disease of the United States Department of Health and Human Services. Archived from the original on 23 May 2019. Retrieved 13 March 2021.
  69. ^ "Understanding and Explaining Viral Vector COVID-19 Vaccines". Centers for Disease Control and Prevention. Archived from the original on 2 February 2021. Retrieved 13 March 2021.
  70. ^ Garde, Damian; Feuerstein, Adam (1 November 2020). "How nanotechnology helps mRNA Covid-19 vaccines work". STAT. Archived from the original on 1 December 2020. Retrieved 21 December 2020.
  71. ^ CDC (11 February 2020). "COVID-19 and Your Health". Centers for Disease Control and Prevention. Archived from the original on 3 March 2021. Retrieved 21 December 2020.
  72. ^ Banks, Marcus A. (16 July 2020). "What Are mRNA Vaccines, and Could They Work Against COVID-19?". Smithsonian Magazine. Archived from the original on 21 December 2020. Retrieved 21 December 2020.
  73. ^ Branswell, Helen (19 December 2020). "FDA grants authorization to Moderna's Covid-19 vaccine". STAT. Archived from the original on 21 December 2020. Retrieved 21 December 2020.
  74. ^ Cuffari, Benedette (17 March 2021). "What is a DNA Vaccine?". News-Medical.net. Retrieved 2024-01-14.
  75. ^ "DNA Vaccines". World Health Organization. Retrieved 2024-01-14.
  76. PMID 19944973
    .
  77. PMID 24872109
    .
  78. ^ McKenzie, David (26 May 2018). "Fear and failure: How Ebola sparked a global health revolution". CNN. Archived from the original on 26 August 2019. Retrieved 26 May 2018.
  79. PMID 19388175
    .
  80. ISBN 978-1-904455-35-6. Archived
    from the original on 2008-04-11. Retrieved 2008-04-15.
  81. ^ "Monovalent" at Dorland's Medical Dictionary
  82. ^ "Polyvalent vaccine". Dorland's Medical Dictionary. 2012-03-07. Archived from the original on 2012-03-07.
  83. ^ "Questions And Answers On Monovalent Oral Polio Vaccine Type 1 (mOPV1)'Issued Jointly By WHO and UNICEF'". Pediatric Oncall. 2 (8). 3. What advantages does mOPV1 have over trivalent oral polio vaccine (tOPV)?. 2005-01-08. Archived from the original on 2012-02-29.
  84. PMID 18020577
    .
  85. ^ Sutter RW, Cochi SL, Melnick JL (1999). "Live attenuated polio vaccines". In Plotkin SA, Orenstein WA (eds.). Vaccines. Philadelphia: W. B. Saunders. pp. 364–408.
  86. PMID 11312014
    .
  87. PMID 16763072
    .
  88. ^ Sox, Harold C.; Liverman, Catharyn T.; Fulco, Carolyn E.; War, Institute of Medicine (US) Committee on Health Effects Associated with Exposures During the Gulf (2000). Vaccines. National Academies Press (US). Archived from the original on 2021-11-16. Retrieved 2019-05-03.
  89. ^ "Institute for Vaccine Safety – Thimerosal Table". Archived from the original on 2005-12-10.
  90. ^ Wharton, Melinda E.; National Vaccine Advisory committee "U.S.A. national vaccine plan" Archived 2016-05-04 at the Wayback Machine
  91. ^ "Measurements of Non-gaseous air pollutants > Metals". npl.co.uk. National Physics Laboratory. Archived from the original on 29 September 2007. Retrieved 28 June 2020.
  92. ^ "Thimerosal in vaccines". Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. 2007-09-06. Archived from the original on 2013-01-06. Retrieved 2007-10-01.
  93. S2CID 11570020
    .
  94. S2CID 36318722
    .
  95. ^ "Another study, this one of 657k kids, finds MMR vaccine doesn't cause autism". National Post. 2019-03-05. Retrieved 2019-03-13.
  96. ISSN 0362-4331. Archived
    from the original on 2019-03-12. Retrieved 2019-03-13.
  97. ^ CDC (2018-07-12). "Ingredients of Vaccines – Fact Sheet". Archived from the original on December 17, 2009. Retrieved December 20, 2009.
  98. ^ The mercury levels in the table, unless otherwise indicated, are taken from Mercury Levels in Commercial Fish and Shellfish (1990–2010) Archived 2015-05-03 at the Wayback Machine U.S. Food and Drug Administration. Accessed 8 January 2012.
  99. ^ a b Centers for Disease Control and Prevention (12 November 2020), U.S. Vaccine Names, archived from the original on 2021-08-21, retrieved 2021-08-21.
  100. ^ a b Centers for Disease Control and Prevention (2018-08-07), Tetanus (Lockjaw) Vaccination, archived from the original on 2016-05-16, retrieved 2016-05-21.
  101. ^ Centers for Disease Control and Prevention (2018-02-02), Vaccine Acronyms and Abbreviations [Abbreviations used on U.S. immunization records], archived from the original on 2017-06-02, retrieved 2017-05-22.
  102. ^ a b c d e f g h i "Principles and considerations for adding a vaccine to a national immunization programme" (PDF). World Health Organization. 1 April 2014. Archived (PDF) from the original on 29 September 2020. Retrieved 17 August 2020.
  103. PMID 34348117
    .
  104. ^
    PMID 26439108
    .
  105. ^ Offit, Paul A. (2020). "Making vaccines: Licensure, recommendations and requirements". Children's Hospital of Philadelphia. Archived from the original on 8 September 2020. Retrieved 20 August 2020.
  106. ^ a b Toner E, Barnill A, Krubiner C, Bernstein J, Privor-Dumm L, Watson M, et al. (2020). Interim Framework for COVID-19 Vaccine Allocation and Distribution in the United States (PDF) (Report). Baltimore, MD: Johns Hopkins Center for Health Security. Archived (PDF) from the original on 22 August 2020. Retrieved 24 August 2020.
  107. PMID 33382671
    .
  108. ^ a b c d e "Vaccine product approval process". U.S. Food and Drug Administration (FDA). 30 January 2020. Archived from the original on 27 September 2020. Retrieved 17 August 2020.
  109. ^ "home". Cdsco.gov.in. 2021-04-15. Archived from the original on 2022-01-04. Retrieved 2022-01-10.
  110. PMID 33712350
    .
  111. ^ "ACIP Vaccine Recommendations Home Page". CDC. 2013-11-15. Archived from the original on 2013-12-31. Retrieved 2014-01-10.
  112. ^ "Vaccine Status Table". Red Book Online. American Academy of Pediatrics. April 26, 2011. Archived from the original on December 27, 2013. Retrieved January 9, 2013.
  113. ^ "HPV Vaccine Safety". Centers for Disease Control and Prevention (CDC). 2013-12-20. Archived from the original on 2009-11-10. Retrieved 2014-01-10.
  114. ^ "HPV vaccine in the clear". NHS choices. 2009-10-02. Archived from the original on 2014-01-10. Retrieved 2014-01-10.
  115. ^ "Zostavax EPAR". European Medicines Agency (EMA). 29 July 2021. Archived from the original on 5 August 2020. Retrieved 1 September 2021.
  116. PMID 33382671. Archived
    (PDF) from the original on 2021-08-19. Retrieved 2021-08-17.
  117. ISSN 2639-9431. Archived
    from the original on 2021-10-09. Retrieved 2021-08-17.
  118. ^ Goodman JL (2005-05-04). "Statement by Jesse L. Goodman, M.D., M.P.H. Director Center for Biologics, Evaluation and Research Food and Drug Administration U.S. Department of Health and Human Services on US Influenza Vaccine Supply and Preparations for the Upcoming Influenza Season before Subcommittee on Oversight and Investigations Committee on Energy and Commerce United States House of Representatives". Archived from the original on 2008-09-21. Retrieved 2008-06-15.
  119. PMID 19059446
    .
  120. PMID 23357859
    .
  121. PMID 24295806
    .
  122. ^ Roser, Max; Vanderslott, Samantha (2013-05-10). "Vaccination". Our World in Data. Archived from the original on 2020-09-01. Retrieved 2019-05-03.
  123. ^ "Increasing Access to Vaccines Through Technology Transfer and Local Production" (PDF). World Health Organization. 2011. Archived (PDF) from the original on 2015-11-23.
  124. ^ Christy Somos (7 May 2021). "Everything you need to know about the WTO's COVID-19 vaccine patent proposal". CTV News. Archived from the original on 23 May 2021. Retrieved 23 May 2021.
  125. ^
    ISBN 978-1-4377-2158-4. Archived
    from the original on April 18, 2023. Retrieved March 26, 2021.
  126. ^
    PMID 28647170
    .
  127. The Washington Post. Archived
    from the original on 19 October 2017.
  128. ^
    PMID 19589753
    .
  129. ^ a b "Components of a vaccine". Archived from the original on 2017-06-13.
  130. ^
    S2CID 9066150
    .
  131. ^ "Vaccine Taskforce Aims" (PDF). assets.publishing.service.gov.uk. 6 April 2020. Archived (PDF) from the original on 2020-07-26. Retrieved 2020-07-26.
  132. PMID 32600908
    .
  133. ^ Miller, Joe; Kuchler, Hannah (2020-04-28). "Drugmakers race to scale up vaccine capacity". www.ft.com. Archived from the original on 2022-12-10. Retrieved 2020-07-26.
  134. ^
    ISBN 978-0-323-39301-0
    .
  135. PMID 15191787
    .
  136. ^ American Medicine. American-Medicine Publishing Company. 1926.
  137. ^ South African Institute for Medical Research (1929). Annual report [Jaarverslag]. South African Institute for Medical Research – Suid-Afrikaanse Instituut vir Mediese Navorsing.
  138. ISBN 978-1-4398-2009-4
    .
  139. PMID 16564111
    .
  140. ^ WHO to trial Nanopatch needle-free delivery system| ABC News, 16 Sep 2014| "Needle-free polio vaccine a 'game-changer'". ABC News. 2014-09-16. Archived from the original on 2015-04-02. Retrieved 2015-09-15.
  141. ^ "Australian scientists develop 'needle-free' vaccination". The Sydney Morning Herald. 18 August 2013. Archived from the original on 25 September 2015.
  142. ^ "Vaxxas raises $25m to take Brisbane's Nanopatch global". Business Review Weekly. 2015-02-10. Archived from the original on 2015-03-16. Retrieved 2015-03-05.
  143. ^ "Australian scientists develop 'needle-free' vaccination". The Hindu. Chennai, India. 28 September 2011. Archived from the original on 1 January 2014.
  144. ^ "Needle-free nanopatch vaccine delivery system". News Medical. 3 August 2011. Archived from the original on 11 May 2012.
  145. PMID 19402200
    .
  146. ^
    PMID 12884166
    .
  147. PMID 3011974
    .
  148. ^
    PMID 10486928
    .
  149. PMID 2169682
    .
  150. PMID 8023552
    .
  151. PMID 8350404
    .
  152. S2CID 22827454
    .
  153. PMID 17027123
    .
  154. PMID 21419163. Archived
    from the original on 2017-10-28.
  155. ISBN 978-0-521-63262-1
    .
  156. ^
    ISBN 978-0-230-27471-6
    .
  157. ISBN 978-0-08-091946-1
    .
  158. ^ Voltaire (1742). "Letter XI". Letters on the English. Archived from the original on 2018-10-16. Retrieved 2023-07-26.
  159. ISBN 92-4-156110-6
    .
  160. ^
    PMID 6390027
    .
  161. ^
    PMID 15886151
    .
  162. PMID 8653442. Archived from the original
    (PDF) on 2011-07-08.
  163. ^ Exhibition tells story of Spanish children used as vaccine fridges in 1803 Archived 2022-08-30 at the Wayback Machine The Guardian, 2021
  164. doi:10.1093/jhmas/jrn014
    .
  165. PMID 20789814
    .
  166. ISBN 978-0-12-801171-3
    .
  167. PMID 26579097
    ;
  168. ^
    PMID 10050276
    .
  169. PMID 11050940
    .
  170. ^ Naftalis, Kramer Levin; Royzman, Frankel LLP-Irena; Pineda, ré (30 November 2020). "Third-Generation Vaccines Take Center Stage in Battle Against COVID-19 | Lexology". www.lexology.com. Archived from the original on 30 January 2021. Retrieved 24 January 2021.
  171. ^ Regalado, Antonio. "The U.S. government has begun testing its first Zika vaccine in humans". Archived from the original on 2016-08-21. Retrieved 2016-08-06.
  172. PMID 26344472
    .
  173. ^ "Katalin Karikó and Drew Weissman Awarded Horwitz Prize for Pioneering Research on COVID-19 Vaccines". Columbia University Irving Medical Center. 2021-08-12. Archived from the original on 2021-08-16. Retrieved 2021-09-07.
  174. The Japan Times. Agence France-Presse – Jiji Press. Archived
    from the original on 30 March 2013. Retrieved 2013-03-28.
  175. S2CID 40130001
    .
  176. S2CID 38323966
    .
  177. PMID 19200833
    .
  178. PMID 12531364
    .
  179. S2CID 23987319
    .
  180. ^ a b Leonhardt, David (March 11, 2024). "The Fourth Anniversary of the Covid Pandemic". The New York Times. Archived from the original on March 11, 2024. "Data excludes Alaska. Sources: C.D.C. Wonder; Edison Research. (Chart) By The New York Times. Source credits chart to Ashley Wu.
  181. S2CID 115201206
    .
  182. PMID 26337737
    .
  183. PMID 24598724
    .
  184. S2CID 237437018. Archived
    from the original on 2023-12-24. Retrieved 2022-06-24.
  185. PMID 29147039
    .
  186. ^ "Why do some people oppose vaccination?". Vox. Archived from the original on 2019-09-21. Retrieved 2018-11-26.
  187. ^ Ceccarelli L. "Defending science: How the art of rhetoric can help". The Conversation. Archived from the original on 2019-11-05. Retrieved 2018-11-26.
  188. ^ U.S. Department of Health and Human Services. "Vaccines.gov". Vaccines.gov. Archived from the original on 2019-03-13. Retrieved 2018-08-05.
  189. ^ "Frequently Asked Questions (FAQ)". Boston Children's Hospital. Archived from the original on October 17, 2013. Retrieved February 11, 2014.
  190. PMID 26978210
    .
  191. PMID 12193361. Archived
    from the original on 2006-08-25. Retrieved 2008-01-14.
  192. S2CID 39229852
    .
  193. ^ Wallace A (2009-10-19). "An epidemic of fear: how panicked parents skipping shots endangers us all". Wired. Archived from the original on 2013-12-25. Retrieved 2009-10-21.
  194. S2CID 1978650
    .
  195. ^ "Ten threats to global health in 2019". Who.int. Archived from the original on 2019-06-27. Retrieved 2020-12-09.
  196. ^ PM, Aristos Georgiou (2019-01-15). "The anti-vax movement has been listed by WHO as one of its top 10 health threats for 2019". Archived from the original on 2019-11-22. Retrieved 2019-01-16.

Further reading

External links

Wikiquote has quotations related to Vaccines.
External videos
video icon Modern Vaccine and Adjuvant Production and Characterization,
Genetic Engineering & Biotechnology News
Retrieved from "https://en.wikipedia.org/w/index.php?title=Vaccine&oldid=1219105240#Types"